Hey A8人卵巢癌細胞、H
具體成交價以合同協議為準
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號
- 產地
- 廠商性質 生產廠家
- 更新時間 2025/8/6 13:14:02
- 訪問次數 93
聯系方式:陳壽彬18956075901 查看聯系方式
聯系我們時請說明是化工儀器網上看到的信息,謝謝!
人卵巢癌細胞HEY A8
種屬 | 人 |
別稱 | HEY-A8; Hey-A8; Hey A8; HEYA8; HeyA8 |
組織來源 | 卵巢 |
疾病 | 肺小細胞癌 |
傳代比例/細胞消化 | 1:2傳代,貼壁消化1-2分鐘 |
培養基配置 | DMEM培養基;10%胎牛血清;1%雙抗 |
形態 | 上皮細胞樣 |
生長特征 | 貼壁生長 |
STR | Amelogenin X CSF1PO 10,11 D2S1338 24,25 D3S1358 16 D5S818 11,12 D7S820 12 D8S1179 13,14 D13S317 11 D16S539 8,12 D18S51 15 D19S433 13,14 D21S11 30 FGA 20,21 TH01 8,9.3 TPOX 11 vWA 16,17 |
倍增時間 | 每周 2 至 3 次 |
outcomes. Clinical analyses have also revealed unprecedented heterogeneity in tumor and stromal biology of PDAC, underscoring the need for more personalized approaches and combinatorial therapies. This review will highlight the current state of translational research focusing on PDAC immunity, summarize ongoing clinical efforts to tackle PDAC vulnerabilities, and underscore some unresolved challenges in implementing therapies more broadly. A better